

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-39 (Canceled).

Claim 40 (Currently Amended): A recombinant adenoviral vector derived from a human adenovirus comprising an exogenous nucleotide sequence encoding all or part of an antibody, wherein said all or part of an antibody is capable of recognizing a tumor antigen or an epitope specific for an infectious and pathogenic organism, wherein said all or part of an antibody is modified at the N-terminus by fusion to extracellular domains I and II of CD4, and wherein said exogenous nucleotide sequence is under the control of elements necessary for expression of said modified antibody.

Claim 41 (Previously Presented): The recombinant adenoviral vector according to Claim 40, wherein said antibody is selected from the group consisting of a native antibody, a chimeric antibody, an antibody fragment and a bispecific antibody.

Claims 42-45 (Canceled).

Claim 46 (Previously Presented): The recombinant adenoviral vector according to Claim 40, wherein it is defective for replication.

Claim 47 (Previously Presented): The recombinant adenoviral vector according to Claim 46, wherein it lacks at least all or part of the E1 region and, optionally, all or part of the E3 region.

Claims 48-50 (Canceled).

Claim 51 (Previously Presented): The recombinant adenoviral vector according to Claim 40, wherein the elements necessary for the expression comprise a promoter selected from the group consisting of the adenoviral early promoter E1A, the late promoter MLP (Major Late Promoter), the murine or human PGK (Phosphoglycerate kinase) promoter, the SV40 virus early promoter, the RSV (Rous Sarcoma virus) virus promoter, and a tumor-specific promoter.

Claim 52 (Previously Presented): An infectious viral particle comprising a recombinant adenoviral vector according to Claim 40.

Claim 53 (Previously Presented): A eukaryotic host cell comprising a recombinant adenoviral vector according to Claim 40.

Claim 54 (Previously Presented): A pharmaceutical composition comprising a recombinant adenoviral vector according to Claim 40, in association with a pharmaceutically acceptable carrier.

Claim 55 (Previously Presented): The pharmaceutical composition according to Claim 54, comprising  $10^4$  to  $10^{14}$  pfu.

Claim 56 (Previously Presented): The pharmaceutical composition according to Claim 54, wherein it is in injectable form.

Claims 57-60 (Canceled).